



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 13/06, A61K 31/70	A1	(11) International Publication Number: WO 00/11010 (43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/US99/19063 (22) International Filing Date: 18 August 1999 (18.08.99) (30) Priority Data: 09/138,305 21 August 1998 (21.08.98) US (71) Applicant: RIBI IMMUNOCHEM RESEARCH, INC. [US/US]; 553 Old Corvallis Road, Hamilton, MT 59840 (US). (72) Inventors: ELLIOTT, Gary, T.; 100 College Street, Stevensville, MT 59870 (US). WEBER, Patricia, A.; 327 Main Street, Stevensville, MT 59870 (US). SOWELL, C., Gregory; 20520 Bothell/Everett Hwy., #D-107, Bothell, WA 98012 (US). (74) Agents: KULLICK, Ronald, H.; Ribi ImmunoChem Research, Inc., 553 Old Corvallis Road, Hamilton, MT 59840 (US) et al.		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE (57) Abstract The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2- Deoxy-6-O- [2-deoxy-4-O -phosphono-3-O -[(R)-3- tetradecanoyloxytetradecanoyl] -2-[(R)-3- octadecanoyloxytetradecanoylamino] -β-D-glucopyranosyl] -2-[(R)-3- hexadecanoyloxytetradecanoylamino] -D-glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.		